Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2017

Open Access 01-12-2017 | Review

Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Authors: Carlos Chaccour, Felix Hammann, N. Regina Rabinovich

Published in: Malaria Journal | Issue 1/2017

Login to get access

Abstract

Ivermectin is an endectocide that has been used broadly in single dose community campaigns for the control of onchocerciasis and lymphatic filariasis for more than 30 years. There is now interest in the potential use of ivermectin regimens to reduce malaria transmission, envisaged as community-wide campaigns tailored to transmission patterns and as complement of the local vector control programme. The development of new ivermectin regimens or other novel endectocides will require integrated development of the drug in the context of traditional entomological tools and endpoints. This document examines the main pharmacokinetic and pharmacodynamic parameters of the medicine and their potential influence on its vector control efficacy and safety at population level. This information could be valuable for trial design and clinical development into regulatory and policy pathways.
Appendix
Available only for authorised users
Literature
1.
Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–11.CrossRefPubMedPubMedCentral
2.
Durnez LC, Coosemans M. Residual transmission of malaria: an old issue for new approaches. In: Anopheles Mosquitoes–new insights into malaria vectors. Manguin S, editor. InTech; 2014.
3.
4.
Ranson H, Lissenden N. Insecticide resistance in African Anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control. Trends Parasitol. 2016;32:187–96.CrossRefPubMed
5.
6.
Shoop WL, Mrozik H, Fisher MH. Structure and activity of avermectins and milbemycins in animal health. Vet Parasitol. 1995;59:139–56.CrossRefPubMed
7.
8.
9.
Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.CrossRefPubMedPubMedCentral
10.
11.
Meyers JI, Gray M, Kuklinski W, Johnson LB, Snow CD, Black WC, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol. 2015;218:1478–86.CrossRefPubMedPubMedCentral
12.
Menez C, Sutra JF, Prichard R, Lespine A. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (−/−) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis. 2012;6:e1883.CrossRefPubMedPubMedCentral
13.
Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103:539–47.CrossRefPubMed
14.
Gardner K, Meisch MV, Meek CL, Biven WS. Effects of ivermectin in canine blood on Anopheles quadrimaculatus, Aedes albopictus and Culex salinarius. J Am Mosq Control Assoc. 1993;9:400–2.PubMed
15.
Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988;35:681–4.CrossRefPubMed
16.
Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6.CrossRefPubMedPubMedCentral
17.
Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet. 2000;355:43–4.CrossRefPubMed
18.
Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis. 2005;41:e5–8.CrossRefPubMed
19.
Homeida MM, Malcolm SB, ElTayeb AZ, Eversole RR, Elassad AS, Geary TG, et al. The lack of influence of food and local alcoholic brew on the blood level of Mectizan((R)) (ivermectin). Acta Trop. 2013;127:97–100.CrossRefPubMed
20.
Miyajima A, Hirota T, Sugioka A, Fukuzawa M, Sekine M, Yamamoto Y, et al. Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies. J Dermatol. 2016;43:1030–6.CrossRefPubMed
21.
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010;38:D237–43.CrossRefPubMed
22.
Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96:1698–705.CrossRefPubMedPubMedCentral
23.
Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, et al. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther. 2003;73:P94.CrossRef
24.
25.
Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502.CrossRefPubMed
26.
Jani M, Makai I, Kis E, Szabo P, Nagy T, Krajcsi P, et al. Ivermectin interacts with human ABCG2. J Pharm Sci. 2011;100:94–7.CrossRefPubMed
27.
Chiu SH, Lu AY. Metabolism and Tissue Residues. In: Campbell WC, editor. Ivermectin and abamectin. New York: Springer; 1989. p. 131–43.CrossRef
28.
Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42:79–81.PubMed
29.
Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407–10.CrossRefPubMed
30.
Lam J, Baello S, Iqbal M, Kelly LE, Shannon PT, Chitayat D, et al. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res. 2015;78:417–21.CrossRefPubMed
31.
Lankas GR, Minsker DH, Robertson RT. Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol. 1989;27:523–9.CrossRefPubMed
32.
Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313–21.CrossRefPubMed
33.
Treluyer JM, Cheron G, Sonnier M, Cresteil T. Cytochrome P-450 expression in sudden infant death syndrome. Biochem Pharmacol. 1996;52:497–504.CrossRefPubMed
34.
Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics. 1997;7:441–52.CrossRefPubMed
35.
Chiu SH, Taub R, Sestokas E, Lu AY, Jacob TA. Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab Rev. 1987;18:289–302.CrossRefPubMed
36.
Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. In: Campbell WC, editor. Ivermectin and abamectin. New York: Springer; 1989. p. 113–30.CrossRef
37.
Kobylinski K, Davidson S, Jittamala P, Pukrittayakamee S, Hanboonkunupakarn B, van der Pluijm R, et al. Mosquito-lethal efficacy of ivermectin, dihydroartemisinin–piperaquine, and primaquine: Ivermectin for Malaria in Southeast Asia (IMSEA Study). Oral presentation during the 65th Annual Meeting of the ASTMH Atlanta 2016. 2016.
38.
Smit M, Ochomo E, ter Kuile F. Efficacy and safety of high-dose ivermectin for reducing malaria transmission: A dose finding study (IVERMAL). Oral presentation during the 65th Annual Meeting of the ASTMH Atlanta 2016.
39.
Lespine A, Menez C, Bourguinat C, Prichard RK. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2012;2:58–75.CrossRefPubMed
40.
Alvinerie M, Dupuy J, Kiki-Mvouaka S, Sutra JF, Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet Parasitol. 2008;157:117–22.CrossRefPubMed
41.
Hugnet C, Lespine A, Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharm Pharm Sci. 2007;10:311–8.PubMed
42.
Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357–65.CrossRefPubMed
43.
Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong’o B, Bayoh N, et al. Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya. JMIR Res Protoc. 2016;5:e213.CrossRefPubMedPubMedCentral
44.
Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.CrossRefPubMedPubMedCentral
45.
Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119–26.CrossRefPubMedPubMedCentral
46.
47.
Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.CrossRefPubMedPubMedCentral
48.
Seaman JA, Alout H, Meyers JI, Stenglein MD, Dabire RK, Lozano-Fuentes S, et al. Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals. BMC Genom. 2015;16:797.CrossRef
49.
Slater H, Kobylinski KC, Foy B, Alout H, Churcher T, Bousema T, Ghani A. Ivermectin for malaria control: model validation to existing data and designing trials to detect an impact using clinical and entomological metrics. In 64th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2015 Oct 25–29; Philadelphia.
50.
Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972–80.CrossRefPubMed
51.
Foy BD, Alout H, Seaman JA, Coulidiaty AGV, Bougma R, Rouamba N, et al. Update on Repeat Ivermectin Mass Drug Administrations for control of MALaria (RIMDAMAL): a randomized pilot safety and efficacy study (poster). In: 64th annual meeting of the American Society of Tropical Medicine and Hygiene 2015 Philadelphia, USA.
52.
Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016;8:365ra157.
53.
Chaccour C, Barrio A, Gil Royo AG, Martinez Urbistondo D, Slater H, Hammann F, et al. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J. 2015;14:102.CrossRefPubMedPubMedCentral
54.
International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36.CrossRef
55.
Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, et al. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop. 2012;121:34–43.CrossRefPubMed
56.
Kobylinski K, Ubalee R, Ponlawat A, McCardle W, Foy B, Szumlas D, et al. Ivermectin inhibits the development of Plasmodium vivax in Anopheles dirus. 64th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2015 Oct 25–29; Philadelphia USA.
57.
da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205:1278–86.CrossRefPubMedPubMedCentral
58.
Pinilla Y, Lopes S, Fabri C, Sampaio V, Melo G, Lacerda M, et al. Effect of ivermectin on Plasmodium vivax in its interaction with Anopheles aquasalis (poster). 65th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2016 Nov 11–17; Atlanta, USA.
59.
60.
Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.CrossRefPubMedPubMedCentral
61.
Golan DT, AH; Armstrong, EJ; Armstrong, AW. Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd Ed. Philadelphia. USA: LWW; 2011.
62.
Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122–33.CrossRefPubMed
63.
64.
65.
66.
Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2003;2(Suppl 1):S5.CrossRefPubMedPubMedCentral
67.
Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004;98:496–504.CrossRefPubMed
68.
Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS, et al. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. Am J Trop Med Hyg. 1995;52:94–7.PubMed
69.
Ejere HO, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev. 2012;8:CD002219.PubMedCentral
70.
Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18–22.CrossRefPubMed
71.
72.
73.
Zoure HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5:e1210.CrossRefPubMedPubMedCentral
74.
D’Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7:286re4.CrossRefPubMed
75.
Drame PM, Meng Z, Bennuru S, Herrick JA, Veenstra TD, Nutman TB. Identification and validation of Loa loa microfilaria-specific biomarkers: a rational design approach using proteomics and novel immunoassays. MBio. 2016;7:e02132.CrossRefPubMedPubMedCentral
76.
Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62:334–41.CrossRefPubMed
77.
78.
79.
80.
81.
Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet. 1990;336:1486–9.CrossRefPubMed
82.
Brown KR. Changes in the use profile of Mectizan: 1987–1997. Ann Trop Med Parasitol. 1998;92(Suppl 1):S61–4.CrossRefPubMed
83.
Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk. Eur J Clin Pharmacol. 1993;45:389–90.CrossRefPubMed
84.
Chaccour C, Rabinovich NR. Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway. Malaria J (submitted).
85.
Chaccour CJ, Del Pozo JL. Case 23-2012: a man with abdominal pain and weight loss. N Engl J Med. 2012;367:1670–1.CrossRefPubMed
86.
Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect. 2005;50:375–81.CrossRefPubMed
87.
Becourt C, Marguet C, Balguerie X, Joly P. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol. 2013;169:931–3.CrossRefPubMed
88.
Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet. 1997;349:1144–5.CrossRefPubMed
89.
90.
Coyne PE, Addiss DG. Deaths associated with ivermectin for scabies. Lancet. 1997;350:215–6 (author reply 16).CrossRefPubMed
91.
92.
Reintjes R, Hoek C. Deaths associated with ivermectin for scabies. Lancet. 1997;350:215 (author reply 16).CrossRefPubMed
93.
94.
Dukuly ZD, Pacque M, Nara A, Taylor HR, Williams PN, Greene BM. A prospective study in high risk subjects of electrocardiographic changes with ivermectin. Trop Med Parasitol. 1990;41:73–4.PubMed
95.
Kipp W, Burnham G, Kamugisha J. Improvement in seizures after ivermectin. Lancet. 1992;340:789–90.CrossRefPubMed
96.
Halley BA, VandenHeuvel WJ, Wislocki PG. Environmental effects of the usage of avermectins in livestock. Vet Parasitol. 1993;48:109–25.CrossRefPubMed
97.
Wall R, Strong L. Environmental consequences of treating cattle with the antiparasitic drug ivermectin. Nature. 1987;327:418–21.CrossRefPubMed
98.
Barth D, Heinze-Mutz EM, Langholff W, Roncalli RA, Schluter D. Colonisation and degradation of dung pats after subcutaneous treatment of cattle with ivermectin or levamisole. Appl Parasitol. 1994;35:277–93.PubMed
99.
100.
Awadzi K, Opoku NO, Addy ET, Quartey BT. The chemotherapy of onchocerciasis. XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 1995;46:131–7.PubMed
101.
Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg. 1999;93:189–94.CrossRefPubMed
102.
Doumbo O, Soula G, Kodio B, Perrenoud M. Ivermectin and pregnancy in mass treatment in Mali (in French). Bull Soc Pathol Exot. 1992;85:247–51.PubMed
103.
Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg. 1993;87:318.CrossRefPubMed
104.
Gyapong JO, Chinbuah MA, Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health. 2003;8:1093–101.CrossRefPubMed
105.
Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med Hyg. 2008;79:856–63.PubMed
Metadata
Title
Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety
Authors
Carlos Chaccour
Felix Hammann
N. Regina Rabinovich
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2017
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-017-1801-4

Other articles of this Issue 1/2017

Malaria Journal 1/2017 Go to the issue

Methodology

Malaria surveys using rapid diagnostic tests and validation of results using post hoc quantification of Plasmodium falciparum histidine-rich protein 2

Research

Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study

Research

Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976–78

Research

Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand

Opinion

Seasonal malaria chemoprevention: successes and missed opportunities

Case Study

Effectiveness and equity of the Tanzania National Voucher Scheme for mosquito nets over 10 years of implementation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits